tetano
Editor, Senior Moderator
Sci Rep
. 2024 Oct 23;14(1):25028.
doi: 10.1038/s41598-024-72449-1. Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial
Fabrice Bonnet[SUP] 1 2 [/SUP], Adama Doumbia[SUP] 3 4 [/SUP], Vanessa Machault[SUP] 5 [/SUP], Frederic Nogbou Ello[SUP] 3 4 [/SUP], Pantxika Bellecave[SUP] 6 [/SUP], Corine Bernice Akpovo[SUP] 3 4 [/SUP], Baba Toumany Sidibe[SUP] 4 [/SUP], Laura Fernandez[SUP] 7 [/SUP], Antoine Kouamé[SUP] 3 [/SUP], Edgard Adjogoua[SUP] 8 [/SUP], Mireille Dosso[SUP] 8 [/SUP], Serge Niangoran[SUP] 3 [/SUP], Valérie Journot[SUP] 5 [/SUP], Serge Paul Eholié[SUP] 9 10 11 [/SUP]
Affiliations
Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins. We implemented a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavir (LPVr) on the SARS-CoV-2 nasopharyngeal viral load in patients with mild / moderate COVID-19 infection in Côte d'Ivoire. RT-PCR positive COVID-19 patients ≥ 18 years, with general or respiratory symptoms for less than 7 days were randomized (1:1:1) to receive LPVr (400 mg/100 mg twice daily), LPVr + TLM (10 mg once daily) or LPVr + ATV (20 mg once daily) for 10 days. The primary endpoint was viro-inflammatory success defined as a composite variable at day 11: Ct ≥ 40 and C-reactive protein < 27 mg/L. We randomized 294 patients: 96 to LPVr, 100 to LPVr + TLM, 98 to LPVr + ATV arms. Baseline characteristics were well balanced between arms. In the primary analysis (missing = failure), 46% patients in the LPVr arm reached viro-inflammatory success at day 11 vs 43% in the LPVr + TLM arm (p = 0.69) and 43% in the LPVr + ATV arm (p = 0.68). The median time from baseline to resolution of COVID-19 related symptoms was not different between arms. Nine patients were hospitalized: 2 in the LPVr arm, 5 in the LPVr + TLM arm and 2 in the LPVr + ATV arm and 4 patients died. Among adults with mild to moderate COVID-19 infection, the addition of telmisartan or atorvastatin, to the standard LPVr treatment is not associated with a better virological or clinical outcome.Trial registration: NCT04466241, registered on 10/07/2020.
Keywords: Atorvastatin; Randomized controlled trial; SARS-CoV-2; Telmisartan.
. 2024 Oct 23;14(1):25028.
doi: 10.1038/s41598-024-72449-1. Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial
Fabrice Bonnet[SUP] 1 2 [/SUP], Adama Doumbia[SUP] 3 4 [/SUP], Vanessa Machault[SUP] 5 [/SUP], Frederic Nogbou Ello[SUP] 3 4 [/SUP], Pantxika Bellecave[SUP] 6 [/SUP], Corine Bernice Akpovo[SUP] 3 4 [/SUP], Baba Toumany Sidibe[SUP] 4 [/SUP], Laura Fernandez[SUP] 7 [/SUP], Antoine Kouamé[SUP] 3 [/SUP], Edgard Adjogoua[SUP] 8 [/SUP], Mireille Dosso[SUP] 8 [/SUP], Serge Niangoran[SUP] 3 [/SUP], Valérie Journot[SUP] 5 [/SUP], Serge Paul Eholié[SUP] 9 10 11 [/SUP]
Affiliations
- PMID: 39443527
- DOI: 10.1038/s41598-024-72449-1
Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins. We implemented a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavir (LPVr) on the SARS-CoV-2 nasopharyngeal viral load in patients with mild / moderate COVID-19 infection in Côte d'Ivoire. RT-PCR positive COVID-19 patients ≥ 18 years, with general or respiratory symptoms for less than 7 days were randomized (1:1:1) to receive LPVr (400 mg/100 mg twice daily), LPVr + TLM (10 mg once daily) or LPVr + ATV (20 mg once daily) for 10 days. The primary endpoint was viro-inflammatory success defined as a composite variable at day 11: Ct ≥ 40 and C-reactive protein < 27 mg/L. We randomized 294 patients: 96 to LPVr, 100 to LPVr + TLM, 98 to LPVr + ATV arms. Baseline characteristics were well balanced between arms. In the primary analysis (missing = failure), 46% patients in the LPVr arm reached viro-inflammatory success at day 11 vs 43% in the LPVr + TLM arm (p = 0.69) and 43% in the LPVr + ATV arm (p = 0.68). The median time from baseline to resolution of COVID-19 related symptoms was not different between arms. Nine patients were hospitalized: 2 in the LPVr arm, 5 in the LPVr + TLM arm and 2 in the LPVr + ATV arm and 4 patients died. Among adults with mild to moderate COVID-19 infection, the addition of telmisartan or atorvastatin, to the standard LPVr treatment is not associated with a better virological or clinical outcome.Trial registration: NCT04466241, registered on 10/07/2020.
Keywords: Atorvastatin; Randomized controlled trial; SARS-CoV-2; Telmisartan.